EUVIMEDEUVIMED entdecken
Vergleichsstudie

Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats

Neha Laxane, Khushwant S Yadav iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-01 · 399 (1) · 797-814

DOI: 10.1007/s00210-025-04460-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 18.07.2025. Verfasst von Neha Laxane und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS (Deemed to Be University), Mumbai, India. Hauptthemen laut MEDLINE: Paclitaxel, Imatinib Mesylate, Nanoparticles, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current study investigates the therapeutic potential of paclitaxel (PX) co-loaded with imatinib (IMT), IMT with protamine (PT), and gefitinib (GF) nanoparticle (NP) formulations against triple-negative breast cancer (TNBC) to overcome drug resistance. Building upon our previous work where the SR-F-I (PX-IMT-PLGA NPs), SR-F-I (coated) as PX-IMT-PT-PLGA-NPs, and SR-F-II (PX-GF-PLGA NPs) formulations were optimized and evaluated in both MCF-7 and MCF-7/ADR cells, we extended our investigation to MDA-MB-231 TNBC cells and in vivo animal model. Comparative in vitro cytotoxicity studies demonstrated that SR-F formulations, especially SR-F-I (coated) and SR-F-II, significantly enhanced drug delivery and cell death compared to free PX and combination conventional drug solutions. Confocal imaging confirmed improved NP internalization, correlating with increased cytotoxic efficacy. In vivo, SR-F formulations exhibited reduced tumor growth volumes, lower prostaglandin-2 (PGs-2) levels, and diminished tumor markers (tumor necrosis factor-alpha; TNF-α and breast cancer Antigen 15-3; CA 15-3), indicating reduced inflammation and tumor burden. Histopathological evaluations of SR-F formulations revealed improved tissue repair and organized fibrosis in mammary tissue. Our findings thus highlight the superior potential of co-loaded polymeric NPs in targeted cancer therapy, with an enhanced safety profile, therapeutic outcomes, and modulation of systemic inflammation. The co-loaded formulation of PX with IMT and GF presents a promising strategy for advancing breast cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelImatinib MesylateNanoparticlesTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAnimalsFemaleProtaminesHumansPolylactic Acid-Polyglycolic Acid CopolymerCell Line, TumorGefitinibRatsMCF-7 CellsAntineoplastic AgentsCell SurvivalDrug CarriersRats, Sprague-Dawley

Stichwörter der Autor:innen

Co-loaded PLGA nanoparticlesDMBA-induced breast cancerGefitinibImatinibPaclitaxelTriple-negative breast cancer

Substanzen

PaclitaxelProtaminesPolylactic Acid-Polyglycolic Acid CopolymerImatinib MesylateGefitinibAntineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS (Deemed to Be University), Mumbai, India.
  • Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS (Deemed to Be University), Mumbai, India. khush.yadav@gmail.com.

ORCID-Profile: Khushwant S Yadav

Zitieren

APA

Laxane, N., & Yadav, K. S. (2026). Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(1), 797-814. https://doi.org/10.1007/s00210-025-04460-w

Vancouver

Laxane N, Yadav KS. Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(1):797-814. doi:10.1007/s00210-025-04460-w

BibTeX
@article{Laxane2026,
  author = {Laxane, Neha and Yadav, Khushwant S},
  title = {Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {1},
  pages = {797--814},
  doi = {10.1007/s00210-025-04460-w}
}
Kostenlos starten →